Therapeutic agent for treating prostatic diseases and method of treating prostatic diseases

FIELD: medicine.

SUBSTANCE: present group of inventions refers to medicine, namely to urology, and concerns treating prostatic diseases. That is ensured by administering a therapeutic agent containing an activated-potentiated form of prostate-specific antigen antibody and using the activated-potentiated form of endothelial NO-synthase antibodies as an additional exalting agent.

EFFECT: administering this combined therapeutic agent provides the effective treatment of the prostatic diseases by the synergetic effect of the ingredients consisting in intensifying the antiproliferative, anti-inflammatory effects and improving the functional state of the prostate.

10 cl, 1 ex

 

The invention relates to medicine and can be used to treat the urinary system diseases, in particular diseases of the prostate.

The prior art known drug for the treatment of diseases of the prostate gland containing the activated form of ultra-low doses of antibodies to prostatespecific antigen (EN 2192889 C1, A61K 39/395, 20.11.2002). However, this drug is not in all cases provide adequate therapeutic efficacy.

In addition, it is known the use of the drug "Avala" on the basis of activated forms of ultra-low doses of antibodies to prostatespecific antigen for the treatment of patients with benign prostatic hyperplasia (BPH), which advanced to improve the quality of erection was prescribed a drug on the basis of activated forms of ultra-low doses of antibodies to endothelial NO-synthase "impose" (Zyrianov A.G. Clinical efficacy of drugs "Atala" and "impose" in the treatment of prostatic hyperplasia in combination with erectile dysfunction. Bulletin Of Buryat Gosuniversiteta. 2009/12, p.129-130 (1); Zyrianov GD, Zyrianov A.G. and other Clinical efficacy Atala and Impaza in the treatment of prostatic hyperplasia in combination with erectile dysfunction.

The third Congress of surgeons of Siberia and the Far East the eye. Tomsk, October 15-16, 2009, proceedings of the Congress s-279 (2); Kalinin, S., Selipanov O.L. and other Diagnosis and treatment of patients with benign prostatic hyperplasia. Topical issues of urology. Collection of scientific works. Saint-Petersburg. 2007, C-130 (3)).

In this case, the first drug "Afala used as a primary drug for the treatment of benign prostatic hyperplasia and was prescribed 2 tablets 4 times a day, and the second drug "Impaza used to improve the quality of erections and assigned daily: 1 time per day 2 tablets or 1 tablet 2 times a day, that is, the drugs were taken in different quantities and at different times. This fact allows us to assume that each of the products worked independently from each other and produces her own, due to its pharmacological properties, therapeutic effect.

Furthermore, in D1 - D2 was used "Avala" for the treatment of hypertrophy (hyperplasia) and prostate cancer. The results were evaluated by standard questionnaires. Evaluated the quality of life of patients by questionnaire.

Because these patients simultaneously suffering from sexual disorders, they were simultaneously prescribed drug "impose".

From D1 D2 it follows that the use of 2 drugs each patient with erectile dysfunction was administered to patients to t the th, in order to improve their quality of life compared to patients with BPH without erectile dysfunction. The drug "Avala"containing the active substance in homeopathic doses, is a safe drug that does not cause side effects, and does not, unlike inhibitors of 5-a-reductase and blockers, oppression of sexual function.

The study has confirmed the previously known properties inherent in each product separately:

1) safety, tolerability properties of both drugs),

2) reducing the symptoms of BPH (properties Avala"),

3) improvement of erectile function (properties impose").

Each of the drugs were applied by manufacturer's recommended treatment regimens: 4 admission "Atala" and 1 reception "impose" in a day or 2 tablets at the reception.

The study has not been established factors drug interactions or any new, unknown effects at their simultaneous application.

Thus, we can say that in this publication D1 D2 reflects the fact that concurrent administration of drugs with the aim of playing at the individual patient known to each drug properties, but not the fact that they are combined (combined, simultaneous and in the same dose) applied to treatment of a single disease.

From D3, it follows that for patients Leche is of BPH, presenting complaints also reduce erection in the first group was administered the complex therapy of α-blockers and Avala", and the second group of α-blockers and Prostamol-DNA. The results revealed that combination therapy of BPH using "Atala" is more efficient than using Prostamol-DNA.

In parallel to improve the quality of erections (quality of life) both groups received the drug "impose", as well as the rate of hardware vacuum treatment, which was accompanied by improvement of sexual function.

As part of a comprehensive treatment of BPH "Avala" was prescribed by manufacturer's recommended scheme: 2 tablets 4 times a day during the week, and then 2 tablets 2 times a day. "Impose" is probably also on the recommended developed scheme for 12 weeks (detailed descriptions are not).

Thus, as in the D1 - D2, and D3, "Atala" and "impose" was used in patients simultaneously for the treatment of different diseases, BPH and erectile dysfunction. Any impact on the symptoms of BPH "impose or symptoms of erectile dysfunction "Avala" were found. When this joint application "Avala", α-blockers and impose" improves the quality of life of patients normalizes impaired in BPH urination, increases sexual function, i.e. when the joint use of drugs by various the output circuits introduction to maintain their known pharmacological properties without creating a new therapeutic effect, and, therefore, therapeutic effect of the drug "Avala" for the treatment of BPH introduction of the drug "impose" does not improve.

The invention is directed to the creation of medicines in the form of a pharmaceutical composition for enhancing the effectiveness of treatment of diseases of the prostate based on the activated - potentiated form of antibodies to prostatespecific antigen.

The solution of this problem is provided by the fact that drug for the treatment of diseases of the prostate gland, containing activated - potentiated form of antibodies to prostatespecific antigen (PSA), according to the invention, made in the form of pharmaceutical compositions and includes extra reinforcing component activated - potentiated form of antibodies to endothelial NO-synthase.

The activated - potentiated form of antibodies to prostatespecific antigen (PSA) and the activated - potentiated form of antibodies to endothelial NO-synthase is used in the form of activated - potentiated aqueous or aqueous - alcoholic solution obtained in the process of consecutive multiple-dilution in water or water-alcohol solvent and an intermediate external mechanical impact - vertical shaking.

Pharm is Titicaca composition of the claimed medicinal product can be made in solid dosage form, which contains an effective amount of granules neutral media saturated with a mixture of aqueous or aqueous-alcoholic solutions of the activated - potentiated form of antibodies to prostatespecific antigen (PSA) and activated - potentiated form of antibodies to endothelial NO-synthase, and pharmaceutically acceptable additives. While pharmaceutically acceptable additives include lactose, cellulose microcrystalline and magnesium stearate.

Aqueous or aqueous-alcoholic solutions of the activated-potentiated form of antibodies to prostatespecific antigen (PSA) and to endothelial NO-synthase obtained by repeated consecutive dilution and intermediate external influence from the matrix solutions of affinity purified antibodies to prostatespecific antigen (PSA) and to endothelial NO-synthase with a concentration of 0.5÷5.0 mg/ml

Each of the components of ultra-low doses of affinity purified antibodies are used in the form of a mixture of various, mainly centesimal homeopathic dilutions.

Each of the existing components is a mixture of different centesimal homeopathic dilutions.

Preferably, the drug contains an activated - potentiated form of antibodies to prostatespecific antigen and to endothelial NO-synthase in midget the first dose of each component, made with a matrix solution and diluted to 10012in the 10030100200that is equivalent to a mixture of centesimal homeopathic dilution C12, C30 and C200.

The solution of this problem is provided by the fact that in the method of treatment of diseases of the prostate by introducing into the body an activated - potentiated form of antibodies to prostatespecific antigen, according to the invention, optionally simultaneously and co-injected activated - potentiated form of ultra-low doses of affinity purified antibodies to endothelial NO-synthase.

While the disease prostate cancer selected from the group including, including: benign hyperplasia of the prostate stage I and II, dysuric disorders (frequent urge to urinate, difficulty during urination, pain and discomfort in the crotch area).

Furthermore, the method of treatment and prevention with the use of the claimed medicinal product can be used in complex therapy in men suffering from prostate cancer, including before and after surgery of the prostate gland, and in the treatment of acute and chronic prostatitis as anti-inflammatory and analgesic.

When this activated - potentiated forms of the antibodies to prostatespecific antigen and activated - potentiated form of antibodies to endothelial NO-synthase is used in the form of activated - potentiated aqueous or aqueous-alcoholic solution of each component, obtained in the process of consecutive multiple-dilution in water or water-alcohol solvent and an intermediate external mechanical impact - vertical shaking.

Preferably used is prepared in the form of a single drug - single dosage form a mixture of homeopathic dilutions of antibodies to prostatespecific antigen in combination with a mixture of homeopathic dilutions of antibodies to endothelial NO-synthase.

In addition, the drug contains active components in the ratio 1:1, with each component used in the form of a mixture of three corresponding matrix solutions, diluted in 10012, 10030and the 100200once that is equivalent to boast of homeopathic dilutions With 12, 30, 200.

The claimed pharmaceutical composition is recommended, preferably, 1-2 tablets 2-4 times a day.

When treating diseases of the prostate may separate, but combined (simultaneous) application (organism) in the form of two separately prepared drugs in the form of solutions and in the solid is medicinal forms (pills), each of which contains activated - potentiated form of ultra-low doses of affinity purified antibodies to prostatespecific antigen (PSA) and, accordingly, the activated - potentiated form of ultra-low doses of affinity purified antibodies to endothelial NO-synthase.

The proposed combination of activated - potentiated forms of antibodies to prostatespecific antigen (PSA) and to endothelial NO-synthase in the pharmaceutical composition (i.e., the form of antibodies to prostatespecific antigen (PSA) and to endothelial NO - synthase, prepared according to homeopathic technology exponentiation by repeated consecutive dilution and intermediate external effects - vertical shaking, which have activity in pharmacological models and/or clinical methods of treatment of diseases of the prostate) provides an unexpected synergistic therapeutic effect, confirmed by adequate experimental models and clinical studies, which is to strengthen antigenome (antiproliferative) effect in enhancing anti-inflammatory effect and is manifested by normalization of the functional state of the prostate and lower urinary tract, the improvement of the urodynamics. Declared tools which can be used when conservative therapy, as well as in patients with BPH who underwent surgery to reduce the size of the prostate gland activates regenerative-repair processes in patients undergoing surgery for BPH, reduces the likelihood of developing complications after surgery. In addition, the claimed technical solution to improve the quality of life of patients with benign prostatic hyperplasia (BPH), prostatitis and other diseases of the prostate, reduces dysuric disorders, have a vegetal stabilizing effect. This technical result is due to endotheliopathy action of the activated - potentiated form of antibodies to endothelial NO - synthase, which enhances the antiproliferative and anti-inflammatory activity of the activated-potentiated form of antibodies to PSA, including the effect of the activated - potentiated form of antibodies to endothelial NO - synthase in the transduction of intracellular signals, at their simultaneous and sharing in the form of the integrated product.

While the claimed technical solution is characterized by the breadth of therapeutic effects and can be used for a wide range of indications related to diseases of the genitourinary system, t is vozdushniye diseases of the prostate, including in the complex therapy.

In addition, the claimed medicinal product expands the Arsenal of drugs intended for the treatment of diseases of the prostate.

For making an activated - potentiated form of active components, using monoclonal or, mostly, polyclonal antibodies, which can be obtained by known technologies - techniques are described, for example, in the book: Immunological methods, Ed. by Grimes, M, "Medicine", 1987, p.9-33; or, for example, article Laffly, E., R. Sodoyer Hum. Antibodies. Monoclonal and recombinant antibodies, 30 years after. - 2005 - Vol.14. - N 1-2. P.33-55.

Monoclonal antibodies receive, for example, using hybridoma technology. Moreover, the initial stage of the process includes immunization, based on the principles already developed in the preparation of polyclonal antisera. Further stages include obtaining hybrid cells that produce clones of the same specificity of antibodies. Their separation into individual form is carried out in the same manner as in the case of polyclonal antisera.

Polyclonal antibodies can be obtained by active immunization of animals. For this purpose a specially designed circuit animals make a series of injections required in accordance with the invention substances - antigens: simple is tospecification antigen (PSA) and endothelial NO-synthase. As a result of this procedure is to obtain monospecific antisera with high content of antibodies that is used to produce the activated - potentiated forms. If necessary, conduct the purification of antibody present in anticigarette, for example, by the method of affinity chromatography, by application of salt fractionation by precipitation or ion exchange chromatography.

Preferred for the preparation of the claimed pharmaceutical compositions is the use of polyclonal antibodies to prostatespecific antigen (PSA) and to endothelial NO-synthase, which as a matrix (primary) solution with a concentration of 0.5÷5.0 mg/ml, is used for the subsequent preparation of the activated - potentiated form.

Preferred for the preparation of each component is the use of a mixture of three aqueous-alcohol dilutions of the initial matrix solution of antibodies, diluted, respectively, in the 10012, 10030and the 100200time, which corresponds to boast of homeopathic dilutions 12, C30 and 200.

Preferred for the preparation of the claimed medicinal preparation is the use of polyclonal antibodies to prostatespecific antigen (PSA) and endothelial NO-synthase, which can be obtained by immunization of rabbits the following way.

Example 1.

For the experimental studies were used antibodies, cooked to order specialized pharmaceutical company.

Polyclonal antibodies to prostatespecific antigen (PSA) receive, using as immunogen (antigen) for immunization of rabbits with adjuvant whole molecule prostatespecific antigen following sequence:

It is possible to obtain polyclonal antibodies to prostatespecific antigen (PSA) using as immunogen (antigen) one polypeptide fragment prostatespecific antigen, selected, for example, of the following amino acid sequences:

Before taking the blood sample for 7-9 days spend 1-3 intravenous injection for raising antibodies. In the process of immunization in rabbits take small blood samples to estimate the number of antibodies. The maximum level of immune response to the introduction of most soluble antigens is achieved in 40-60 days after the first injection. After completion of the first cycle immunization of rabbits for 30 days to give to restore health and are reimmunization including 1-3 intravenous injection. To obtain antisera from monitorowania rabbits collect the blood in a centrifuge tube with a volume of 50 ml. Using a wooden spatula to remove from the walls of the tube formed clots and put the wand in the clot formed in the center of the tube. The blood is placed in a refrigerator (4°C) overnight. The next day remove the clot adhered to the spatula, and centrifuged remaining liquid at 13000g for 10 minutes the Supernatant (supernatant) is anticorodal. The resulting anticavity should be yellow. Add to anticigarette 20% (weight concentration) NaN3to a final concentration of 0.02% and stored until use in a frozen state at -20°C. For allocation from the antisera antibody prostatespecific antigen (PSA) is produced by absorption on a solid phase in the following sequence:

1. 10 ml of rabbit antisera diluted 2 times with 0.15 M NaCl, type of 6.26 g PA2SO4, mixed and incubated for 12-16 h at 4°C;

2. The precipitation is removed by centrifugation, dissolved in 10 ml of phosphate buffer and then cialiswhat against the same buffer overnight at room temperature;

3. After removal of the precipitate by centrifugation, the solution was applied to the column with DEAE-cellulose, equilibrated with phosphate buffer;

4. The fraction of antibodies determined by measuring the optical density of the eluate at 280 nm.

Then make a clean antibody methodology is affinity chromatography obtained by attaching antibodies to prostatespecific antigen (PSA), which is insoluble matrix followed by elution with concentrated salt solutions.

Obtained, thus, the buffer solution of polyclonal rabbit antibodies to prostatespecific antigen (PSA), purified on antigen, with a concentration of 0.5÷5.0 mg/ml, preferably 2,0÷3,0 mg/ml, used as a matrix (primary) solution for the subsequent preparation of the activated - potentiated form.

Polyclonal antibodies to endothelial NO-synthase get similar to the above method, using as immunogen (antigen) for immunization of rabbits with adjuvant whole molecule endothelial NO-synthase following sequence:

It is possible to obtain polyclonal antibodies to endothelial NO-synthase using as immunogen (antigen) of whole molecules of endothelial NO-synthase following sequence:

It is possible to obtain polyclonal antibodies to endothelial NO-synthase using as immunogen (antigen) a synthetic peptide of endothelial NO-synthase, selected, for example, of the following amino acid sequence is:

The activated - potentiated form of each component is prepared by uniformly reducing the concentration in the serial dilutions 1 of the above matrix solution of 9 parts (for decimal dilution) or 99 parts (for centesimal dilution), or in 999 parts (for the thousandth breeding) neutral solvent with multiple vertical shaking ("dynamics") of each received cultivation and use separate containers for each subsequent breeding until you get the desired potency - ratio cultivation in homeopathic method (see, for example, Usabe "Homeopathic medicinal product", M, 1967, p.14-29).

External processing in the process of reducing the concentration can be realized by ultrasound, electromagnetic or other physical effects.

For example, for the preparation of the 12th centesimal dilution C12 one part of the mentioned matrix solution of antibodies to prostatespecific antigen (PSA) or NO-synthase) with a concentration of 3.0 mg/ml diluted in 99 parts of a neutral aqueous or aqueous-alcoholic solvent (mostly 70% ethyl alcohol) and repeatedly (10 times or more) vertically shaken - potentiate received 1st somenoe C1 breeding. From the 1st centesimal C1 breeding wearable is toulaud 2nd somenoe breeding C2. This operation is repeated 11 times, getting 12th somenoe breeding 12. Thus, 12th somenoe breeding With 12 represents the solution obtained by diluting consistently in different tanks 12 times the 1st part of the initial matrix solution of antibodies to prostatespecific antigen (PSA) concentration of 3.0 mg/ml in 99 parts of a neutral solvent, i.e. the solution obtained by dilution of the matrix solution in the 10012time. Similar operations with a corresponding multiplicity of cultivation is performed to obtain dilutions With 30 and 200.

When used as a biologically active liquid component of the mixture of different homeopathic, mainly centesimal, dilutions, each component of the composition (for example, 12, 30, 200) prepare separately for the above-described technology to their penultimate cultivation (respectively, to obtain 11, s, 199) and then applied in accordance with the composition of the mixture in one container, one part of each component and mixed with the required amount of solvent (respectively, with 97 parts for centesimal dilution). You get the activated - potentiated form of antibodies to prostatespecific antigen (PSA) in ultra-low dose of prepared matrix solution and diluted to 10012in the 10030100200that is equivalent to a mixture SOT the R homeopathic dilutions 12, The C30 and C2000.

It is possible to use components in a mixture of different homeopathic dilutions, for example, the decimal or centesimal (D 20, 30, 100 or C12, C30, with50 etc), the effectiveness of which is determined experimentally.

When potentiation instead of shaking in the process of reducing the concentration can also be external effects of ultrasound, electromagnetic or other physical effects.

To obtain the claimed pharmaceutical compositions are aqueous or aqueous-alcoholic solutions of the active components are mixed, predominantly, in the ratio of 1:1 and used in liquid dosage form.

The claimed pharmaceutical composition can be used in solid dosage form that contains an effective amount of granules neutral media - lactose, saturated by soaking up the saturation a mixture of aqueous or aqueous-alcoholic solutions of the activated - potentiated form of antibodies to prostatespecific antigen (PSA) and activated - potentiated form of antibodies to endothelial NO-synthase, and pharmaceutically acceptable additives, including, primarily, lactose, cellulose microcrystalline and magnesium stearate.

For solid oral forms of the claimed medicinal product produced in the plant boiling the layer (for example, type "Hüttlin Pilotlab" production company Hüttlin GmbH) irrigation until saturation of injected fluid - fluidized bed granules of neutral matter - of lactose (milk sugar) with a particle size of 150÷300 μm, a pre-obtained aqueous or aqueous-alcoholic solution of activated - potentiated forms of antibodies to prostatespecific antigen and endothelial synthase nitric oxide (NO-synthase), mainly in the ratio of 1 kg of the solution of antibodies to 5 or 10 kg of lactose (1:5-1:10) with simultaneous drying in a stream supplied under the grate of heated air at a temperature not exceeding 40°C. the Estimated number 0,17÷0,34 by weight of the solid oral form) dried granules, saturated activated - potentiated form of antibodies, are loaded into the mixer and mixed with microcrystalline cellulose, enter the number 3÷8 mass. parts by weight of the total load from the mass of solid oral forms. Then to this mixture 25÷45 mass. parts by weight of the total load "unsaturated" pure lactose (to reduce the cost and some simplification and acceleration of the process without reducing the effectiveness of therapeutic effects), magnesium stearate in an amount of 0.1÷0.3 mass. parts by weight of the total load and microcrystalline cellulose in an amount of 3÷8 mass. parts by weight of the total load. The obtained pellet mass is evenly mixed and tabletirujut direct dry pressing (for example, in tablet press Korsch XL 400) with the formation of round tablets weighing 150÷500 mg. After tabletting get a tablet weight of 300 mg, impregnated with a water-alcohol solution (3,0-6,0 mg/tab.) the activated-potentiated form of antibodies to prostatespecific antigen and NO - synthase in ultra-low dose of each component prepared from a matrix solution and diluted to 10012in the 10030100200that is equivalent to a mixture of centesimal homeopathic dilution C12, C30 and C200.

Preferably the claimed pharmaceutical composition is recommended to take 1-2 tablets 2-4 times a day.

1. Drug for the treatment of diseases of the prostate gland, containing activated - potentiated form of antibodies to prostatespecific antigen, characterized in that it is made in the form of pharmaceutical compositions and contains extra reinforcing component activated - potentiated form of antibodies to endothelial NO-synthase.

2. The drug according to claim 1, wherein the activated - potentiated form of antibodies to prostatespecific antigen and activated - potentiated form of antibodies to endothelial NO-synthase is used in the form of activated - potentiated aqueous or aqueous-alcoholic solution obtained in% the SSE consecutive multiple-dilution matrix solution of the corresponding antibodies in aqueous or aqueous-alcoholic solvent and an intermediate external mechanical impact - vertical shaking.

3. The drug according to claim 1 or 2, characterized in that the pharmaceutical composition is made in solid dosage form and contains an effective amount of granules neutral media saturated with a mixture of activated - potentiated form of antibodies to prostatespecific antigen and activated - potentiated form of antibodies to endothelial NO-synthase, and pharmaceutically acceptable additives.

4. The drug according to claim 1 or 2, characterized in that the aqueous or aqueous-alcoholic solutions of the activated - potentiated form of antibodies to prostatespecific antigen and to endothelial NO-synthase obtained by repeated consecutive dilution and intermediate external influence from the matrix solutions of affinity purified antibodies to prostatespecific antigen and to endothelial NO-synthase with a concentration of 0.5÷5.0 mg/ml

5. The drug according to claim 1 or 2, characterized in that each of the components of ultra-low doses of affinity purified antibodies are used in the form of a mixture of various, mainly centesimal homeopathic dilutions.

6. The drug according to claim 3, characterized in that the pharmaceutically acceptable additives include lactose, cellulose microcrystalline and magnesium stearate.

7. The method of treatment Zab the diseases of the prostate by introducing into the organism activated - potentiated form of antibodies to prostatespecific antigen, characterized in that additionally at the same time co-injected activated - potentiated form of ultra-low doses of affinity purified antibodies to endothelial NO-synthase.

8. The method according to claim 7, characterized in that the activated - potentiated form of antibodies to prostatespecific antigen and activated - potentiated form of antibodies to endothelial NO-synthase is used in the form of activated - potentiated aqueous or aqueous-alcoholic solution of each component, obtained in the process of consecutive multiple-dilution in water or water-alcohol solvent and an intermediate external mechanical impact - vertical shaking.

9. The method of treatment according to claim 7, characterized in that use is prepared in the form of a single drug - single dosage form a mixture of homeopathic dilutions of antibodies to prostatespecific antigen in combination with a mixture of homeopathic dilutions of antibodies to endothelial NO-synthase.

10. Pharmaceutical composition for the treatment of diseases of the prostate gland, containing activated - potentiated form of antibodies to prostatespecific antigen and activated - potentsiala the ing form of antibodies to endothelial NO-synthase.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to an agent for treating benign prostatic hyperplasia. The antiproliferative agent for treating benign prostatic hyperplasia which contains red deer's antler lipids prepared by extraction of the red deer's antlers in a mixture of the solvents ethanol: ethyl acetate: water in the specific environment.

EFFECT: agent is effective for treating benign prostatic hyperplasia.

2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to methods of treating diseases of various aetiologies and injuries of various visceras. Electropunctural pre-examination aims at determining the patient's overall potential and the potential in a point on the body surface at a minimal distance from the viscera to be treated, or in its immediate projection tender zones. A stem cell growth area is stimulated by placing a bee within the sternum. Then, an irritation centre is created using vacuum- or hirudotherapy in a point on the body surface at a minimal distance from the above viscera or in its immediate projection tender zones. The irritation centre is created to be intensive and short-term at the level of the potential in the point below the overall potential, or to be weak and long-term at the level of the potential in a point above the overall potential.

EFFECT: method provides the effective local therapeutic effect on the involved visceral tissues ensured by a combination of the used components of the effect.

2 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to urology, and can be used for treatment of benign hyperplasia of prostate gland. For this purpose dynamic examination of prostate gland is carried out before drug therapy and 3, 6 and 9 months after that. Dynamic examination includes transrectal ultrasound examination (TRUSE) with Dopplerography and sonoelastography (SEG) of prostate gland. Comparison of prostate size values, hyperplasia size, blood flow in capsular and parauretral arteries, blood flow in adenomatous nodes and density of transitory zones of prostate is carried out in SEG. If values of examined parameters by TRUSE data decrease by 15% and more, each parameter is given 1 point. If density of transitory zones of prostate in sonoelastography is higher than 35 KPa, 1 point is given too. As a result if the sum is not less than 4 points, conservative therapy is stopped. If the sum of points is less than 4 points, therapy is continued. Examination is repeated after next 3 months.

EFFECT: method ensures reduction of terms of drug treatment and increase of treatment quality due to possibility of determining indications for complete or partial cancellation of drug treatment within 3-6 months.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is using at least one protease for producing a drug preparation for treating and/or preventing benign prostatic hypertrophy/hyperplasia wherein the drug preparation is acceptable for the oral administration with at least one protease being specified in a group consisting of plant and microorganism proteases, and with at least one protease being administered in the amount of 1 to 100 mg/kg of body weight, and a respective pharmaceutical preparation.

EFFECT: what is shown is reducing high vascular endothelial growth factor in patient's blood under the action of a mixture of enzymes that makes it possible to inhibit angiogenic growth factors (VEGF), thereby leading to lower vascularisation, and reducing benign prostatic hypertrophy/hyperplasia, with the enzymatic therapy under the present invention having no effect on the normal VEGF level.

13 cl, 7 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely urology, and may be used for treating suppurative septic complications of prostate adenoma. For this purpose, with underlying administering antibiotics, ozonised saline solution in the concentration of 3 to 6 mg/l in the amount of 200 to 400 ml is additionally intravenously administered; the therapeutic course is 3-5 injections depending on the patient's state. Besides, ozonised saline solution in the concentration of 5 to 8 mg/l is injected into the bladder in the preoperative preparation period, and from the second postoperative day, saline solution is introduced drop-by-drop in the amount of 400.0 ml daily five times with a two-way flushing system.

EFFECT: method enables reducing the risk of urosepsis, eliminating intoxication and accelerating postoperative wound healing of a BPH bed by anti-inflammatory, detoxification, analgesic action, improved blood rheology and microcirculation, increased local immunity with activated regenerative and reparative processes.

2 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (1), in which Ar is a group of formula (Ar-1) or (Ar-2), in which R1 is a halogen, R2 is hydrogen, R3 is hydrogen, R4 is hydrogen, alkyl or alkenyl, X is a nitrogen atom or CH, R5 and R6 are each hydrogen and h equals 1; 1 equals 1 or 2; m equals 1 or 2; n equals 0, 1 or 2; o equals an integer from 0 to 3, under the condition that n and o are equal to 0 at the same time. Values of group A are as given in claim 1 of the invention. Described also is a pharmaceutical composition having agonistic activity with respect to 7 serotonin (5-HT4-receptors), which contains a compound of formula (1) and an agent which stimulates enterokinesis or improves functioning of the alimentary canal, which contains a compound of formula (1) as an active ingredient.

EFFECT: novel compounds are obtained and described, which have strong affinity towards 4 serotonin receptors, which are useful as an agent which stimulates enterokinesis or an agent which improves functioning of the alimentary canal.

28 cl, 233 ex, 29 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to urology, and can be used for treatment of chronic abacterial prostatitis in men, which is not connected with dysfunction of urethral sphincter. For this purpose, efficient amount of fispemiphene is introduced to patient who needs it. Introduction of fispemiphene is performed in amount in the range from 0.1 to approximately 100 mg/kg of body weight.

EFFECT: invention ensures efficient treatment of abacterial prostatitis at the early stage of disease where only histological changes of prostate gland are present without presence of urethral sphincter dysfunction, with drug fispemiphene, which demonstrates antagonistic activity to estrogen receptors in particular with respect to prostate tissue.

2 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutical industry, in particular to composition, which contains epigallocatechine-3-gallate as active component and target additive. Pharmaceutical composition for peroral introduction, which contains epigallocatechine-3-gallate and block-copolymer of oxyethylene and oxypropylene, in which content of hydrophobic block constitutes not less than 50 wt %, and molecular weight of hydrophilic block constitutes 2250 Dalton and not more, with specified weight ratio of epigallocatechine-3-gallate and block copolymer 1:1-10:1. Application of upper described pharmaceutical composition for treatment of atopic dermatitis, Crohn's disease, adenomyosis, and hyperplastic diseases of prostate.

EFFECT: composition has increased bioavailability in peroral application, improves absorption of active compound epigallocatechine-3-gallate in blood flow.

6 cl, 2 dwg, 4 tbl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacy, namely technology of preparation of rectal suppositories. The suppositories with solid licorice extract consist of solid licorice extract 0.75 g on a hydrophilic base, polyethylene glycol 6000 1.25 g and polyethylene glycol polystear 0.25 g.

EFFECT: making the preparations exhibiting anti-inflammatory action, and also a positive effect on the hormonal status and the copulative function.

7 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel acid-additive salts of pyrrolopyrimidinone derivative, represented by formula (1) which is selected from gentisate, maleate, citrate, fumarate and semitartrate salts, which possess improved properties in their application, in particular higher stability.

EFFECT: invention also relates to method of obtaining acid-additive salts of pyrrolopyrimidinone derivative, represented by formula (1) and to pharmaceutical composition, containing them, for treatment and prevention of erectile dysfunction, pulmonary arterial hypertension, chronic obstructive lung disease, benign prostate gland hypertrophy and diseases of lower urinary tract.

11 cl, 30 ex, 7 tbl

FIELD: medicine.

SUBSTANCE: invention relates to immunology and biotechnology. In immunochromatographic test-systems along with an analytic zone, intended for binding an analysable compound, usually, applied is a control zone, intended for binding the compound, conjugated with a label. The application of the control zone is necessary to control the functional activity of a reagent, conjugated with the label. If colouring of the control zone is absent, the result of the test is considered invalid. However, in case of the application of immunochromatography for determination of antibodies in blood with the label conjugated is a compound, intended for binding antibodies - further designated as CBAn (compound, binding antibodies). The concentration of antibodies in a sample often exceeds the concentration of CBAn, that is why the concentration of free molecules of CBAn is very low and the disappearance of the control zone in this case does not testify to the malfunction of the conjugate activity. To solve the said problem the claimed invention proposes to add antispecies antibodies against the antibodies sorbed in the control zone, to the conjugate In this case the control zone disappears only in case of loss of the CBAn activity. The antispecies antibodies are added in concentrations considerably lower than the binding ability of the conjugate, in order not to interfere with the interaction of the conjugate with the sample antibodies, as a result of which no considerable reduction of analysis sensitivity is observed.

EFFECT: development of the method of obtaining intermolecular conjugates with colloidal gold, applied in immunochromatographic analysis.

3 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is a group if inventions: a pharmaceutical composition, containing immunologically active enantiomer of a component of the cationic lipid R-DOTAP or S-DOTAP, a method of applying the said enantiomer for induction of an immunostimulating adjuvant effect in the immune system, a method of inducing immune response in a patient with applying thereof and a method of treatment or prevention of a disease in the patient by induction of the immunostimulating adjuvant effect by the lipid.

EFFECT: R-DOTAP and S-DOTAP induced production of cytokines IL-2, IL-8, IL-12, chemokines CCL-5, CCL-19 and tumour regression in mice.

23 cl, 15 dwg, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and can be applied for antitumour immunotherapy. For this purpose, dendritic cells (DC), obtained from a patient's skin, spleen, bone marrow, thymus, lymph nodes, umbilical blood or peripheral blood (autologous DC) are introduced to the patient, with DC being introduced to the patient step-by-step. At the first stage the introduction of mature allogenic DC, loaded with a tumourspecific antigen, maturation of which is realised ex vivo, is performed. At the second stage not less than 24 hours, but not more than 120 hours after the first stage the re-introduction of allogenc DC is realised simultaneously with the introduction of immature autologous DC in situ in a tumour, with the tumour being subjected to an ablation impact preliminarily or simultaneously with DC introduction.

EFFECT: application of the claimed method makes it possible to achieve an increased immune response by the introduction of a two-component immune agent, which consists of a sensitising dose of allogenous mature cells and a therapeutic dose of immature DC, with 10% of the therapeutic DC dose being sufficient for sensitisation.

2 cl, 3 ex

FIELD: biotechnology.

SUBSTANCE: invention is a method of preparing a concentrate of microbial cells for obtaining live tularemia vaccine, which is characterised in that tularemia microbe is grown at a temperature of 37°C for 20±2 hours on the nutrient medium containing, g/l: dry enzymatic hydrolysate of fibrin prepared from waste of whey-vaccine production 50-55, glucose 10, calcium pantothenate 0.05, followed by concentration of the microbial mass by microfiltration of the culture of tularemia microbe through the membranes with the pore size of 0.2 mcm in the mode of tangential liquid flow.

EFFECT: preparing the concentrate of microbial cells of tularemia microbe suitable for obtaining live tularemia vaccine.

1 ex

FIELD: veterinary medicine.

SUBSTANCE: inactivated vaccine for prevention and treatment of trichophytia of cattle comprises elements of the fungus Trichophyton verrucosum - cells and fragments of mycelium, microconidia, arthrospores, chlamydospores; formalin and saline solution in the following ratio of components 1 ml : elements of fungus Trichophyton verrucosum - mycelial fragments, microconidia, arthrospores, chlamydospores 80-120 million, formalin 0.003 ml, saline solution to 1 ml.

EFFECT: increase in duration of immunity up to 30 months, increase in stability of the vaccine and the shelf life of the vaccine to 18 months, the ability of complete removal of the pathogen of trichophytia of cattle from farms, simplification of use of the vaccine, reduction of cost of its production and use, reduction of the load on the immune system of animals.

6 ex, 1 tbl

FIELD: biotechnology.

SUBSTANCE: invention is a liquid medium of drying for stabilisation of biomass of secondary harvesting of plague microbe of vaccine strain EV. The medium comprises 8.0-12.0 g/l medical gelatine; 80.0-120.0 g/l sucrose; 8.0-12.0 g/l thiourea; 2-3 ml of 20% sodium hydroxide solution in flakes, and water for injection up to 1 litre.

EFFECT: invention enables to obtain high-quality liquid medium of drying for stabilisation of biomass of secondary harvesting of plague microbe of vaccine strain EV with enhanced stabilising properties and can be used to prepare suspension for injections, cutaneous scarification application in ampoules in the volume of 1 ml.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapy and cardiology, and concerns correction of the endothelial dysfunction. That is ensured by administering an activated potentiated form of antibodies to endothelial nitrogen oxide synthase in a combination with an activated potentiated form of antibodies to a C-terminal fragment of AT1 angiotensin II receptor.

EFFECT: this combined effect provides effective correction of the endothelial function by the synergetic effect of the activated potentiated form of the antibodies.

4 cl, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology and medicine. What is described is an active immunostimulating vaccine containing at least one RNA, preferentially iRNA coding at least two antigens evoking the immune response in a mammal and used for treating lung cancer, first non-small cells lung cancer (NSCLC), preferentially specified among three primary subtypes, squamous cell carcinoma, adenocarcinoma and large-cell lung carcinoma, or NSCLS-related disorders.

EFFECT: there are produced kits, first containing the active immunostimulating vaccine.

21 cl, 34 dwg, 1 tbl, 8 ex

FIELD: veterinary medicine.

SUBSTANCE: method for production of anti-luteolytic blood - AlB is that luteolisate is administered subcutaneously to gelding twice with an interval of 14 days at a dose of 20 ml each, containing parts of the corpus luteum of pregnancy of cows, and after 14 days after the second administration the blood is taken from the jugular vein. The method of treatment and prevention of persistent corpus luteum, subinvolution of uterus and postpartum endometritis in cows comprises at the background of general therapy the use of anti-luteolytic blood that is administered subcutaneously in the neck region twice at a dose of 10 ml each with an interval of 6 days.

EFFECT: use of anti-luteolytic blood promotes the resorption of the corpus luteum of pregnancy and shortens the duration of postpartum involution of genitals that enables to prevent and reduce the time of treatment of ill cows with persistent corpus luteum, subinvolution of uterus and postpartum endometritis.

2 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present group of inventions refers to medicine, namely to therapy and pharmacology, and can be used to increase pharmacological activity and therapeutic efficacy of drug preparations of activated-potentiated forms of hyperdiluted antibodies. That is ensured by administering a pharmaceutical composition containing activated potentiated pathogenic antigen and endothelial NO-synthase antibodies.

EFFECT: administering this composition provides higher therapeutic efficacy ensured by a synergetic effect of the ingredients of the composition.

10 cl, 18 ex

FIELD: immunotherapeutic agents.

SUBSTANCE: antigenic preparations are obtained from keratinophilic fungi Trichophiton or Microsporum species or yeast species Candida by alkali hydrolysis techniques. Thus obtained preparations can be, in particular used, as vaccines and for treating allergy and modulating immune response.

EFFECT: expanded immunotherapeutic possibilities.

17 cl, 5 dwg, 12 tbl, 20 ex

Up!